TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.
about
Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast CancerMST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer.A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients.TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancerBioinformatics analysis of the prognostic value of Tripartite Motif 28 in breast cancerTP53 mutation hits energy metabolism and increases glycolysis in breast cancer.MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.Gene expression-based prognostic and predictive tools in breast cancer.AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients.Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer.Polypharmacology in Drug Development: A Minireview of Current Technologies.Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.Molecularly targeted therapies for p53-mutant cancers.Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.Threonine and tyrosine kinase may serve as a prognostic biomarker for gallbladder cancer.Correlation analysis between molecular subtypes and Nottingham Prognostic Index in breast cancer.miR-367 stimulates Wnt cascade activation through degrading FBXW7 in NSCLC stem cells.A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer.HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells.Mps1/TTK: a novel target and biomarker for cancer.An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)
P2860
Q26785389-44F17680-B008-4743-A594-F2F8DB37CF34Q30009013-36B215F1-A0F6-4CDF-BCD5-FF78C17F9BAFQ31006978-ACDB2CC0-FD9C-404C-8D4A-F14A49A19E84Q33566957-1A19489C-1ED9-45F1-AC75-AA56531956EFQ33598054-75528185-00D6-4C71-B73E-FDDD0FA80491Q34539146-13F1E2AF-41FE-4470-B358-91C840BD842BQ36545717-EAA52E45-5384-434C-B5D4-C7FD1C981D2CQ36729558-7E62A855-DA36-40AC-8539-0D92B3D97D0FQ38421414-45BBF80F-1F99-476F-9A54-E9921622CC18Q38672995-81BE5820-D7ED-4523-823E-CA27AA858CE7Q38736464-AD32DC88-BC1B-4D81-A7AB-9767C1F34DFBQ38827815-7009E130-8013-4BDA-AD7F-D18B87D5EDA1Q38888022-472C1E06-CD54-48C8-BF04-0ABBC16B1609Q38904176-95BCDEAE-FEB3-49D7-8BEC-AAC3696A1C5EQ39393193-171498EB-83CF-4595-A4F1-84B3D1E1BC20Q41084432-D7BF199D-3319-4BDD-ADF2-50D2173AE117Q41505635-E86B5A1C-324D-4EE7-8536-CA58E3805B86Q47131447-4DCF786C-B469-4CAE-AF87-20A9EDB8AE3CQ47757966-12E8E144-64BF-44F3-8AA4-45F0915FDB88Q47792677-7430AB96-6968-4C7B-B728-D334D6925A40Q49270446-6AB06AAC-4C8B-449F-8529-1ABD3057F2E1Q49283314-59D85555-6831-4DF9-82D2-9A67924C614DQ51074812-A7B9D10E-26AE-4CC1-AB0E-FA57A0ADF296Q52646057-A3892E73-69D4-4B18-B7F1-60712A8FC9DFQ57280932-A59D36D5-E447-4B20-A72D-3F6B550D9D9D
P2860
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
TP53 mutation-correlated genes ...... n TP53-mutated breast cancers.
@en
TP53 mutation-correlated genes ...... n TP53-mutated breast cancers.
@nl
type
label
TP53 mutation-correlated genes ...... n TP53-mutated breast cancers.
@en
TP53 mutation-correlated genes ...... n TP53-mutated breast cancers.
@nl
prefLabel
TP53 mutation-correlated genes ...... n TP53-mutated breast cancers.
@en
TP53 mutation-correlated genes ...... n TP53-mutated breast cancers.
@nl
P2093
P2860
P50
P1433
P1476
TP53 mutation-correlated genes ...... in TP53-mutated breast cancers
@en
P2093
Christos Sotiriou
Gabriel N Hortobagyi
Giampaolo Bianchini
Giulia Bottai
György Kéri
Hugues de Thè
Jacqueline Lehmann-Che
Lajos Pusztai
Nicholas C Turner
Takayuki Iwamoto
P2860
P304
P356
10.1016/J.MOLONC.2013.12.018
P577
2014-01-05T00:00:00Z